US2012022007A1PendingUtilityA1

Method and composition for modulating canonical wnt pathway using folate and inositol

26
Individually held — no corporate assignee on recordPriority: Mar 5, 2009Filed: Sep 6, 2011Published: Jan 26, 2012
Est. expiryMar 5, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Kersti K. Linask
A61P 9/00A61P 3/10A61P 25/28A61K 31/519A61P 19/10A61K 9/08A61P 17/02A61K 31/70A61K 9/0014A61K 31/047
26
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect.

Claims

exact text as granted — not AI-modified
1 . A method of treating a disorder caused by altered canonical Wnt signaling in a patient in need thereof comprising the step of administering a therapeutically effective combination of a folate compound and an inositol compound. 
     
     
         2 . The method of  claim 1  wherein the altered canonical Wnt signaling is caused by elevated homocysteine levels. 
     
     
         3 . The method of  claim 1  wherein the altered canonical Wnt signaling is caused by exposure to a compound selected from the group consisting of lithium and alcohol. 
     
     
         4 . The method of  claim 1 , wherein the disorder is selected from the group consisting of developmental disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), stem cell development and proliferation, wound healing, cancer, Alzheimer's disease, diabetes and osteoporosis. 
     
     
         5 . The method of  claim 1 , wherein the disorder is selected from the group consisting of developmental disorders including neural tube defects and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), and wound healing. 
     
     
         6 . The method of  claim 1  wherein the folate compound is folic acid. 
     
     
         7 . The method of  claim 1  wherein the inositol compound is myo-inositol. 
     
     
         8 . A method of modulating canonical Wnt signaling comprising the step of contacting a target cell population with a therapeutically effective combination of a folate compound and an inositol compound. 
     
     
         9 . The method of  claim 8  wherein the folate compound is folic acid. 
     
     
         10 . The method of  claim 8  wherein the inositol compound is myo-inositol. 
     
     
         11 . A method of preventing the formation of a disorder caused by altered canonical Wnt signaling in a patient at risk therefrom comprising the step of administering a therapeutically effective combination of a folate compound and an inositol compound. 
     
     
         12 . The method of  claim 11 , wherein the disorder caused by altered canonical Wnt signaling is selected from the group consisting of developmental disorders including neural tube defects, limb malformations and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), stem cell development and proliferation, wound healing, cancer, Alzheimer's disease, diabetes and osteoporosis. 
     
     
         13 . The method of  claim 11  wherein the disorder caused by altered canonical Wnt signaling is selected from the group consisting of developmental disorders including neural tube defects and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium) and wound healing. 
     
     
         14 . The method of  claim 11  wherein the altered canonical Wnt signaling is caused by elevated homocysteine levels. 
     
     
         15 . The method of  claim 11  wherein the altered canonical Wnt signaling is caused by the exposure to a compound selected from the group consisting of lithium and alcohol. 
     
     
         16 . The method of  claim 11  wherein the inositol compound is myo-inositol. 
     
     
         17 . The method of  claim 11  wherein the folate compound is folic acid. 
     
     
         18 . A composition comprising:
 a therapeutically effective amount of a folate compound;   a therapeutically effective amount of an inositol compound; and   a pharmaceutically acceptable carrier.   
     
     
         19 . The composition of  claim 18  wherein the folate compound is folic acid. 
     
     
         20 . The composition of  claim 18  wherein the inositol compound is myo-inositol.

Join the waitlist — get patent alerts

Track US2012022007A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.